Search This Blog

Monday, August 10, 2026

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 m upfront plus up to $500 m in milestones

 


  • Deal adds Actio's lead rare epilepsy candidate ABS-1230 to Jazz's neurology and epilepsy portfolio.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)